We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Maximus Weather the VA Contract Hit and Rebuild Earnings Momentum?
Read MoreHide Full Article
Key Takeaways
Maximus cut fiscal 2026 EPS guidance after paused VA incentives removed a key earnings benefit.
MMS lowered EBITDA margin and free cash flow guidance, while revenue guidance remained unchanged.
Maximus sees support from stronger U.S. Services margins and automation and AI-enabled efficiencies.
Maximus, Inc. (MMS - Free Report) faces near-term earnings reset after a temporary change to a major federal contract removed a meaningful profitability contributor for the second half of fiscal 2026.
The central issue for investors is whether that setback stays temporary or underscores the company’s sensitivity to large government programs, even as other operating improvements provide some support.
Maximus Loses a Key Earnings Tailwind Through December
The Department of Veterans Affairs paused performance incentives and disincentives tied to the Medical Disability Exam program from July 1 through Dec. 31, 2026. The mechanism rewards vendors based on measures such as timeliness, accuracy and quality.
Those incentives contributed about 35 cents per share in each of the first three quarters of fiscal 2026. Their removal therefore takes away a material earnings benefit in the fourth quarter and is also expected to affect the first quarter of fiscal 2027 while the pause remains in place.
MMS Cuts Profit Guidance After the Contract Change
Maximus lowered fiscal 2026 adjusted earnings guidance to $7.90-$8.20 per share from $8.25-$8.55. The midpoint declined by 35 cents, matching the approximate quarterly contribution from the paused VA incentives.
Adjusted EBITDA margin guidance fell to about 13.7% from 14.2%. Free cash flow guidance was also reduced to $425-$475 million, showing that the contract changes affects both earnings expectations and cash-generation assumptions, even though full-year revenue guidance remained $5.2-$5.35 billion.
Image Source: Zacks Investment Research
Maximus Federal Exposure Raises Sensitivity
U.S. federal agencies generated 55% of Maximus’ fiscal 2025 revenues, compared with nearly 32% from U.S. state agencies and almost 11% from foreign governments. That mix provides scale and recurring demand but can magnify the impact of contract changes, procurement delays and agency-specific decisions.
The sensitivity is familiar across federal-services peers. Booz Allen Hamilton Holding Corporation (BAH - Free Report) says it depends on U.S. government contracts for substantially all of its revenues. Leidos Holdings, Inc. (LDOS - Free Report) identifies the U.S. government as its largest customer and serves agencies including the Department of Veterans Affairs.
MMS Has Offsets Beyond the VA Program
U.S. Services is moving in a more favorable direction. Third-quarter operating margin improved to 10.8% from 10.2% a year earlier, and management expects positive mid-single-digit organic revenue growth in the fourth quarter, with positive organic growth continuing into fiscal 2027.
Technology is another offset. Maximus said third-quarter adjusted EBITDA margin of 15.0% reflected automation and AI-enabled efficiencies, while management cited broader use of efficiency-enhancing technology across programs. These gains can support profitability, but they do not immediately replace the earnings contribution lost from the paused VA incentives.
Maximus Signals Point to Near-Term Caution
The contract modification looks temporary based on current customer guidance, but it has already reduced fiscal 2026 earnings and cash flow expectations. That makes the pace of any incentive reinstatement, along with execution in U.S. Services and federal procurement timing, important variables for the next phase of earnings momentum.
MMS currently carries a Zacks Rank #5 (Strong Sell).
Maximus carries a VGM Score of A, Value Score of A, Growth Score of B and Momentum Score of B. The favorable Style Scores point to noteworthy valuation, growth and momentum characteristics, but the Zacks Rank reflects weakening earnings estimate revisions and therefore argues for caution in the near term.
Image: Bigstock
Can Maximus Weather the VA Contract Hit and Rebuild Earnings Momentum?
Key Takeaways
Maximus, Inc. (MMS - Free Report) faces near-term earnings reset after a temporary change to a major federal contract removed a meaningful profitability contributor for the second half of fiscal 2026.
The central issue for investors is whether that setback stays temporary or underscores the company’s sensitivity to large government programs, even as other operating improvements provide some support.
Maximus Loses a Key Earnings Tailwind Through December
The Department of Veterans Affairs paused performance incentives and disincentives tied to the Medical Disability Exam program from July 1 through Dec. 31, 2026. The mechanism rewards vendors based on measures such as timeliness, accuracy and quality.
Those incentives contributed about 35 cents per share in each of the first three quarters of fiscal 2026. Their removal therefore takes away a material earnings benefit in the fourth quarter and is also expected to affect the first quarter of fiscal 2027 while the pause remains in place.
MMS Cuts Profit Guidance After the Contract Change
Maximus lowered fiscal 2026 adjusted earnings guidance to $7.90-$8.20 per share from $8.25-$8.55. The midpoint declined by 35 cents, matching the approximate quarterly contribution from the paused VA incentives.
Adjusted EBITDA margin guidance fell to about 13.7% from 14.2%. Free cash flow guidance was also reduced to $425-$475 million, showing that the contract changes affects both earnings expectations and cash-generation assumptions, even though full-year revenue guidance remained $5.2-$5.35 billion.
Maximus Federal Exposure Raises Sensitivity
U.S. federal agencies generated 55% of Maximus’ fiscal 2025 revenues, compared with nearly 32% from U.S. state agencies and almost 11% from foreign governments. That mix provides scale and recurring demand but can magnify the impact of contract changes, procurement delays and agency-specific decisions.
The sensitivity is familiar across federal-services peers. Booz Allen Hamilton Holding Corporation (BAH - Free Report) says it depends on U.S. government contracts for substantially all of its revenues. Leidos Holdings, Inc. (LDOS - Free Report) identifies the U.S. government as its largest customer and serves agencies including the Department of Veterans Affairs.
MMS Has Offsets Beyond the VA Program
U.S. Services is moving in a more favorable direction. Third-quarter operating margin improved to 10.8% from 10.2% a year earlier, and management expects positive mid-single-digit organic revenue growth in the fourth quarter, with positive organic growth continuing into fiscal 2027.
Technology is another offset. Maximus said third-quarter adjusted EBITDA margin of 15.0% reflected automation and AI-enabled efficiencies, while management cited broader use of efficiency-enhancing technology across programs. These gains can support profitability, but they do not immediately replace the earnings contribution lost from the paused VA incentives.
Maximus Signals Point to Near-Term Caution
The contract modification looks temporary based on current customer guidance, but it has already reduced fiscal 2026 earnings and cash flow expectations. That makes the pace of any incentive reinstatement, along with execution in U.S. Services and federal procurement timing, important variables for the next phase of earnings momentum.
MMS currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Maximus carries a VGM Score of A, Value Score of A, Growth Score of B and Momentum Score of B. The favorable Style Scores point to noteworthy valuation, growth and momentum characteristics, but the Zacks Rank reflects weakening earnings estimate revisions and therefore argues for caution in the near term.